Figure 3.

Oxymatrine suppressed the increased percent of ALDH1⁺ TNBC cells induced by Bevacizumab. (A) MDA-MB-231/MDA-MB-468 cells were treated with Oxymatrine/Bevacizumab/Oxymatrine + Bevacizumab for 24 h, then ALDH1⁺ cells were determined by Alderfluor assay and viable cells (7-AAD negative) were used for analysis. DEAB-treated cells were used as negative control. (B) Quantitative analysis of (A). Data were presented as the mean ± SD, n = 3, **P < 0.01 (MDA-MB-231 cells); ##P < 0.01 (MDA-MB-468 cells).